- Charles River’s Q2 revenue met estimates with total revenue of $1.03 billion.
- Total revenue decreased by 3.2% year-over-year.
- Research Models & Services revenue was $206.4 million, down 1.7% from last year.
- Research Models & Services revenue slightly exceeded the estimate of $204.7 million.
- Discovery & Safety Assessment revenue reached $627.4 million, a 5.4% decline year-over-year.
- Discovery & Safety Assessment revenue was just below the estimate of $629.3 million.
- Manufacturing Solutions revenue increased by 3.1% year-over-year to $192.3 million.
- Manufacturing Solutions revenue fell short of the $194.1 million estimate.
- Adjusted EPS for the quarter was $2.80.
- Analyst recommendations include 10 buys, 9 holds, and no sells.
A look at Charles River Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Charles River Laboratories International, Inc. is positioned with a mixed outlook according to Smartkarma Smart Scores. While the company scores moderately well in Value, Growth, and Momentum, its Dividend and Resilience scores are comparatively lower. This suggests that Charles River Laboratories may not be a top choice for dividend-seeking investors but shows promise in terms of growth potential and market momentum.
As a provider of research tools and services crucial for drug discovery and development, Charles River Laboratories caters to a clientele base comprising pharmaceutical and biotechnology firms, hospitals, and academic institutions. With its solid Value, Growth, and Momentum scores, the company appears to be on a positive trajectory for the long term, aligning well with the demands of the healthcare and life sciences sector it serves.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
